Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
580 participants
OBSERVATIONAL
2024-11-04
2029-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF
NCT04198701
PulseSelect™ PFA Global Registry
NCT06393920
A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF
NCT06335082
A Study for Treatment of Paroxysmal Atrial Fibrillation (PAF) by Pulsed Field Ablation (PFA) System With Irreversible Electroporation (IRE)
NCT04524364
ADVENT Post Approval Study
NCT06431815
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Paroxysmal
Ablation using the PulseSelect™ PFA system
PulseSelect™ PFA system
Ablation using the PulseSelect™ PFA system
Persistent
Ablation using the PulseSelect™ PFA system
PulseSelect™ PFA system
Ablation using the PulseSelect™ PFA system
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PulseSelect™ PFA system
Ablation using the PulseSelect™ PFA system
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Refractory to at least one Class I or III antiarrhythmic drug (i.e., not effective, not tolerated, or not desired)
* Patient is ≥ 18 years of age
* Planned pulmonary vein isolation procedure with the commercially available PulseSelect™ PFA System
* Willing and able to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements
Exclusion Criteria
* Prior left atrial catheter or surgical ablation
* Patient with life expectancy \< 36 months
* Presence of a permanent pacemaker, biventricular pacemaker, loop recorder/insertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function)
* Current or anticipated participation in any other clinical trial of a drug, device, or biologic not approved by the global study manager
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic Cardiac Ablation Solutions
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Khaldoun Tarakji, MD
Role: STUDY_DIRECTOR
Medtronic CAS Chief Medical Officer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of South Florida Health (USF)
Tampa, Florida, United States
Pikeville Medical Center
Whitesburg, Kentucky, United States
Southcoast Health System
Fall River, Massachusetts, United States
Beaumont Health System
Royal Oak, Michigan, United States
Nebraska Medical Center
Omaha, Nebraska, United States
The Valley Hospital
New York, New York, United States
Northwell Health Lenox Hill Hospital
New York, New York, United States
Duke University Medical Center (DUMC)
Durham, North Carolina, United States
Bethesda North Hospital
Cincinnati, Ohio, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Mount Carmel Grove City Medical Center
Grove City, Ohio, United States
Doylestown Health Cardiology a division of Doylestown Health Physicians
Doylestown, Pennsylvania, United States
AnMed Health Center
Anderson, South Carolina, United States
Medical University of South Carolina (MUSC)
Charleston, South Carolina, United States
Texas Health Research & Education Institute
Dallas, Texas, United States
University of Virginia Medical Center
Charlottesville, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Kevin Jackson
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PULSED AF PAS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.